Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Eduardo Grunvald, medical director for UC San Diego's Center for Advanced Weight Management, described orforglipron as possibly joining "a growing toolbox of medications for obesity" and called it a potential "game-changer." Convenience determines who can access treatment, who will persist over time, and how many people will consider starting
Diabetes Obes Metab (2017) 19(5):7448
(average results) Wegovy (semaglutide) GLP-1 only In the STEP-1 study (68 weeks), average weight change was about: 14.9% with Wegovy 2.4% with placebo (dummy injection) What that looks like: If you start at 100 kg , 14.9% is about 15 kg lost on average
PMCID: PMC9315959
US$ 20.86
US$ 24.38
US$ 23.07
US$ 28.01
US$ 20.01
US$ 25.01
